PL209129B1 - Nowe związki przeciwnowotworowe - Google Patents

Nowe związki przeciwnowotworowe

Info

Publication number
PL209129B1
PL209129B1 PL377056A PL37705603A PL209129B1 PL 209129 B1 PL209129 B1 PL 209129B1 PL 377056 A PL377056 A PL 377056A PL 37705603 A PL37705603 A PL 37705603A PL 209129 B1 PL209129 B1 PL 209129B1
Authority
PL
Poland
Prior art keywords
compound
cancer
kahalalide
val
compounds
Prior art date
Application number
PL377056A
Other languages
English (en)
Polish (pl)
Other versions
PL377056A1 (pl
Inventor
Glynn Thomas Faircloth
Mariano Elices
Halina Sasak
Marin Pablo Manuel Avilés
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/fr
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharma Mar, Pharma Mar Sau filed Critical Pharma Mar
Publication of PL377056A1 publication Critical patent/PL377056A1/pl
Publication of PL209129B1 publication Critical patent/PL209129B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377056A 2002-10-18 2003-10-20 Nowe związki przeciwnowotworowe PL209129B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (fr) 2001-10-19 2002-10-18 Composes a base de kahalalide utilisables en therapie anticancereuse
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds

Publications (2)

Publication Number Publication Date
PL377056A1 PL377056A1 (pl) 2006-01-23
PL209129B1 true PL209129B1 (pl) 2011-07-29

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377056A PL209129B1 (pl) 2002-10-18 2003-10-20 Nowe związki przeciwnowotworowe

Country Status (13)

Country Link
KR (2) KR101149095B1 (fr)
AT (1) ATE490975T1 (fr)
AU (1) AU2003285911B2 (fr)
CA (1) CA2501089C (fr)
CY (1) CY1111319T1 (fr)
DE (1) DE60335292D1 (fr)
DK (1) DK1572726T3 (fr)
ES (1) ES2357644T3 (fr)
IL (1) IL167724A (fr)
NO (1) NO333448B1 (fr)
PL (1) PL209129B1 (fr)
PT (1) PT1572726E (fr)
SI (1) SI1572726T1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
NZ525243A (en) * 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
EP1435990A1 (fr) * 2001-10-19 2004-07-14 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse

Also Published As

Publication number Publication date
KR20050070056A (ko) 2005-07-05
CY1111319T1 (el) 2015-08-05
ES2357644T3 (es) 2011-04-28
DK1572726T3 (da) 2011-03-28
PL377056A1 (pl) 2006-01-23
CA2501089C (fr) 2012-07-17
PT1572726E (pt) 2011-02-14
ATE490975T1 (de) 2010-12-15
KR20110114690A (ko) 2011-10-19
NO20052379D0 (no) 2005-05-13
AU2003285911A1 (en) 2004-05-04
NO333448B1 (no) 2013-06-10
KR101149095B1 (ko) 2012-05-30
NO20052379L (no) 2005-07-15
IL167724A (en) 2012-01-31
DE60335292D1 (de) 2011-01-20
HK1082261A1 (en) 2006-06-02
CA2501089A1 (fr) 2004-04-29
AU2003285911B2 (en) 2009-11-19
SI1572726T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
US7683028B2 (en) Kahalalide compositions
JP5372096B2 (ja) 新規な抗腫瘍化合物
EP1572726B1 (fr) Composes 4-methylhexanoic kahalalide f
RU2356908C2 (ru) Новые противоопухолевые соединения
PL209129B1 (pl) Nowe związki przeciwnowotworowe
HK1082261B (en) 4-methylhexanoic kahalalide f compound